+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 20Years +
All Genders
ID04962867

Phase 2 Trial of Oral E7090 for Treating Advanced or Recurrent Solid Tumors with FGFR Gene Changes

Led by National Cancer Center, Japan · Updated on 2025-10-03

75

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug E7090 in a Phase 2 clinical trial involving patients with advanced or recurrent solid tumors that have specific FGFR gene alterations. This study aims to assess the effectiveness and safety of E7090 in this group of patients who have tumors with FGFR fusions, mutations, or amplifications. The trial is being conducted at multiple centers and is sponsored by the National Cancer Center in Japan. Participants receive 140 mg of E7090 orally once daily. This is an open-label, single-arm study, meaning all participants receive the same treatment without a comparison group. The study monitors participants over a period of up to 3.5 years to evaluate how their tumors respond to the treatment and to track any side effects or adverse reactions. Throughout the trial, participants undergo regular assessments including tumor measurements using CT or MRI scans, neurological exams for certain tumor types, and laboratory tests for calcium and phosphate levels. Researchers will measure outcomes such as the objective response rate, progression-free survival, overall survival, disease control rate, duration and time to response, as well as adverse event rates. The trial includes a treatment and follow-up period lasting up to 3.5 years to fully assess the drugs impact and safety.

CONDITIONS

Brief Title

NCCH2006/MK010 Trial (FORTUNE Trial)

Research Team

M

Masamichi Takahashi, M.D., Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here